AFP and liver cancer: It is also worth noting that 15.4–30.6% of patients with liver cancer cannot be well diagnosed even when CD166, MCAM, CCT3 and AFP were combined used (Fig. 7g), this led us to discover more useful biomarkers to overcome this problem.